Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use
- PMID: 17044805
- DOI: 10.1517/14740338.5.6.783
Nasal decongestants in the treatment of chronic nasal obstruction: efficacy and safety of use
Abstract
Nasal decongestants are the most powerful drugs in the reduction of nasal obstruction. Despite their large use, local and systemic adverse reactions are frequent. The authors focus on the pharmacology of these kinds of drugs in light of the most recent knowledge on nasal pathophysiology. The ultrastructural anatomy of nasal mucosa explains the complexity of the possible interactions between the sympathomimetics and imidazoles derivates, and the submucosal layer. Nasal obstruction is one of the most frequent clinical problems that otorhinolaryngologists encounter daily, both in adults and children. All possible predisposing conditions to nasal obstruction are documented along with the better ways to diagnose them through nasal functionality tests. Active anterior rhinomanometry, acoustic rhinometry and the determination of mucociliary transport time represent, together with nasal endoscopy, the gold standard for an accurate diagnosis and the follow-up of the patient to cure. An updated review of the most significant works in this field and the best treatment protocol to avoid adverse effects, such as rhinitis medicamentosa, are reported.
Similar articles
-
Rise and fall of decongestants in treating nasal congestion related diseases.Expert Opin Pharmacother. 2024 Oct;25(14):1943-1951. doi: 10.1080/14656566.2024.2411009. Epub 2024 Oct 6. Expert Opin Pharmacother. 2024. PMID: 39344778 Review.
-
Extended use of topical nasal decongestants.Laryngoscope. 1997 Jan;107(1):40-3. doi: 10.1097/00005537-199701000-00010. Laryngoscope. 1997. PMID: 9001263 Clinical Trial.
-
[Ultrastructural changes in human nasal mucosa in rhinitis medicamentosa].HNO. 2006 Oct;54(10):742-8. doi: 10.1007/s00106-005-1370-7. HNO. 2006. PMID: 16477462 German.
-
[Decongestants in treatment of nasal obstruction].Otolaryngol Pol. 1999;53(3):347-52. Otolaryngol Pol. 1999. PMID: 10481510 Review. Polish.
-
[The rebound of nasal resistance after decongestant used in nose].Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1999 Dec;13(12):560-1. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1999. PMID: 12541428 Chinese.
Cited by
-
Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses.GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010;9:Doc07. doi: 10.3205/cto000071. Epub 2011 Apr 27. GMS Curr Top Otorhinolaryngol Head Neck Surg. 2010. PMID: 22073111 Free PMC article.
-
Use, Abuse, and Misuse of Nasal Medications: Real-Life Survey on Community Pharmacist's Perceptions.J Pers Med. 2023 Mar 26;13(4):579. doi: 10.3390/jpm13040579. J Pers Med. 2023. PMID: 37108966 Free PMC article.
-
Rhinitis medicamentosa: what an otolaryngologist needs to know.Eur Arch Otorhinolaryngol. 2009 May;266(5):623-5. doi: 10.1007/s00405-008-0896-1. Epub 2008 Dec 19. Eur Arch Otorhinolaryngol. 2009. PMID: 19096862 Review.
-
Update on Intranasal Medications in Rhinosinusitis.Curr Allergy Asthma Rep. 2017 Jul;17(7):47. doi: 10.1007/s11882-017-0720-3. Curr Allergy Asthma Rep. 2017. PMID: 28602009 Review.
-
Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures.Am J Physiol Lung Cell Mol Physiol. 2021 May 1;320(5):L750-L756. doi: 10.1152/ajplung.00552.2020. Epub 2021 Feb 9. Am J Physiol Lung Cell Mol Physiol. 2021. PMID: 33561380 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical